The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Hyper-CVAD plus nelarabine in the treatment of newly diagnosed patients with T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LL).
A. Al-Ameri
No relevant relationships to disclose
D. A. Thomas
No relevant relationships to disclose
F. Ravandi
No relevant relationships to disclose
S. M. O'Brien
No relevant relationships to disclose
H. Kantarjian
No relevant relationships to disclose
G. Borthakur
No relevant relationships to disclose
T. M. Kadia
Research Funding - GlaxoSmithKline
M. Kelly
No relevant relationships to disclose
R. Garris
No relevant relationships to disclose
S. Faderl
Research Funding - GlaxoSmithKline